We have not explained this story yet. The original headline, summary and link are below.

Moderna (NASDAQ: MRNA) announced that three abstracts for its investigational mRNA-based individualized neoantigen therapy, intismeran autogene, have been accepted for presentation at the European Society for Medical Oncology (ESMO) Congress 2026. These presentations will detail phase 3 study results for resected melanoma, phase I study results for resectable pancreatic ductal adenocarcinoma, and a phase 3 study of adjuvant intismeran autogene for high-risk stage I NSCLC. Moderna will also host a live webcast investor event during the congress to discuss these findings.